BP reductions with EnligHTN ablation system sustained at 1 year

  • May 24, 2013

PARIS — New 6-month and 1-year data from the EnligHTN I first-in-man study demonstrate safety and efficacy of the multielectrode renal denervation system in patients with drug-resistant hypertension.

The prospective, multicenter, feasibility EngligHTN I trial enrolled 46 patients (mean age, 60 years; mean BMI, 32) who were taking at least three antihypertensive medications including a diuretic. Mean baseline BP was 176 mm Hg/96 mm Hg.

Full Story »
  • Filter By:

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

  • Intervention Rx
  • Otamixaban
  • P. Gabriel Steg, MD, and Amir-Ali Fassa, MD, explore an investigational agent for NSTEACS: otamixaban.
More »
  • The Take Home
  • ISET
  • Attendees provide their take-home messages from this year's ISET meeting.
More »
More »
  • In the Journals
  • Perspective
  • Srinivas Iyengar, MD, shares his thoughts on the outcomes of a DES in SFA in-stent restenosis.
More »
[X]